Hormones may change how HIV prevention drug works in the body
NCT ID NCT07672717
First seen Jun 29, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study looks at how natural hormones and hormone therapy (like birth control or gender-affirming hormones) affect the way the HIV prevention drug cabotegravir works in the body. Researchers will measure drug levels in blood, tissues, and fluids in 32 HIV-negative adults. The goal is to understand if hormones change how well the drug prevents HIV, which could help personalize prevention for people on hormone therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cabotegravir (long-acting injectable)
What this could lead to
If successful, this could help tailor HIV prevention strategies for people using hormone therapy, making PrEP more effective for diverse populations.
What could go wrong
This is an early-phase study with only 32 participants, so results may not apply broadly. It focuses on drug levels, not actual HIV prevention outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins School of Medicine, Drug Development Unit
RECRUITINGBaltimore, Maryland, 212187, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••